These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32998751)

  • 1. Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics.
    Sørensen MH; Bojer AS; Jørgensen NR; Broadbent DA; Plein S; Madsen PL; Gæde P
    Cardiovasc Diabetol; 2020 Sep; 19(1):158. PubMed ID: 32998751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
    Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
    Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissipative energy loss within the left ventricle detected by vector flow mapping in diabetic patients with controlled and uncontrolled blood glucose levels.
    Li CM; Bai WJ; Liu YT; Tang H; Rao L
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1151-1158. PubMed ID: 28299608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The additive effects of type 2 diabetes mellitus on left ventricular deformation and myocardial perfusion in essential hypertension: a 3.0 T cardiac magnetic resonance study.
    Li XM; Jiang L; Guo YK; Ren Y; Han PL; Peng LQ; Shi R; Yan WF; Yang ZG
    Cardiovasc Diabetol; 2020 Sep; 19(1):161. PubMed ID: 32998742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The independent association of myocardial extracellular volume and myocardial blood flow with cardiac diastolic function in patients with type 2 diabetes: a prospective cross-sectional cohort study.
    Bojer AS; Sørensen MH; Madsen SH; Broadbent DA; Plein S; Gæde P; Madsen PL
    Cardiovasc Diabetol; 2023 Mar; 22(1):78. PubMed ID: 37004049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes.
    Bojer AS; Sørensen MH; Vejlstrup N; Goetze JP; Gæde P; Madsen PL
    Cardiovasc Diabetol; 2020 Oct; 19(1):184. PubMed ID: 33092588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications.
    Sørensen MH; Bojer AS; Broadbent DA; Plein S; Madsen PL; Gæde P
    Eur Heart J Cardiovasc Imaging; 2020 Aug; 21(8):887-895. PubMed ID: 31642902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
    Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study.
    Liu X; Yang ZG; Gao Y; Xie LJ; Jiang L; Hu BY; Diao KY; Shi K; Xu HY; Shen MT; Ren Y; Guo YK
    Cardiovasc Diabetol; 2018 Oct; 17(1):139. PubMed ID: 30373588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus.
    Leung M; Wong VW; Hudson M; Leung DY
    Circ Cardiovasc Imaging; 2016 Mar; 9(3):e003643. PubMed ID: 26962125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between heart rate variability and left ventricular layer-specific deformation in uncomplicated diabetic patients.
    Vukomanovic V; Tadic M; Suzic-Lazic J; Kocijancic V; Celic V
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):481-490. PubMed ID: 27853970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.
    Swoboda PP; McDiarmid AK; Erhayiem B; Ripley DP; Dobson LE; Garg P; Musa TA; Witte KK; Kearney MT; Barth JH; Ajjan R; Greenwood JP; Plein S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28716801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress.
    Sørensen MH; Bojer AS; Pontoppidan JRN; Broadbent DA; Plein S; Madsen PL; Gæde P
    Diabetes Care; 2020 Jun; 43(6):1285-1292. PubMed ID: 32193248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls.
    Ofstad AP; Urheim S; Dalen H; Orvik E; Birkeland KI; Gullestad L; W Fagerland M; Johansen OE; Aakhus S
    J Diabetes; 2015 Nov; 7(6):779-90. PubMed ID: 25350248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus: The TODAY Follow-Up Study.
    TODAY Study Group
    Circ Heart Fail; 2020 Jun; 13(6):e006685. PubMed ID: 32498621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes.
    Yeo JL; Gulsin GS; Brady EM; Dattani A; Bilak JM; Marsh AM; Sian M; Athithan L; Parke KS; Wormleighton J; Graham-Brown MPM; Singh A; Arnold JR; Lawson C; Davies MJ; Xue H; Kellman P; McCann GP
    Cardiovasc Diabetol; 2022 May; 21(1):85. PubMed ID: 35643571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.